Regorafenib and Cetuximab in Patients With Advanced Malignancy

NCT02095054 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Advanced Cancers

Interventions

DRUG: Regorafenib
DRUG: Cetuximab
BEHAVIORAL: Questionnaire

Sponsor

M.D. Anderson Cancer Center